Skip to Content
Medical SciencesMedical Sciences
  • Editor’s Choice
  • Review
  • Open Access

25 February 2026

24 Pages

Immunotherapies for Ischemic Stroke Patients: Current Status and Future Directions

,
,
and
1
Department of Biomedical Sciences, Southern Illinois University, Carbondale, IL 62901, USA
2
College of Veterinary Medicine, Midwestern University, Glendale, AZ 85308, USA
3
Department of Biomedical Sciences, Midwestern University, Glendale, AZ 85308, USA
4
Department of Neuroscience, Carleton University, Ottawa, ON K1S 5B6, Canada
This article belongs to the Section Cardiovascular Disease

Abstract

Background/Objectives: Ischemic stroke occurs when a thrombus forms within a blood vessel in the brain. This results in reduced levels of oxygen and glucose, leading to the death of cells and a reduction in function. There are several molecular signaling cascades that commence after the onset of an ischemic stroke; these include increases in apoptosis, oxidative stress, neuroinflammation, as well as others. The aim of this review is to provide an updated synthesis of the impact ischemic stroke has on the immune system and how the immune system can be targeted to improve outcomes post-stroke. Methods: In this review, we have included both clinical and pre-clinical studies and provide a discussion for future directions given our synthesis of the data. Results: It is evident that reducing neuroinflammation is an important component of reducing brain tissue loss and functional impairments after stroke. A combination of therapies may be more effective for stroke-affected patients. This could include reducing neuroinflammation through immune therapies, in combination with some pharmaceuticals specific to the patient’s needs. Furthermore, sex differences are highly prevalent in ischemic stroke outcomes. These differences can inform us of the best sex-specific interventions, treatments, or techniques that should be used in healthcare to ensure lower mortality rates and higher quality of life for all. Therapeutic development for ischemic stroke is needed, and this review highlights that targeting the immune system could lead to better outcomes for patients.

1. Introduction

Ischemic stroke occurs when a thrombus forms within a blood vessel in the brain; this results in reduced levels of oxygen and glucose to the specific area of the brain, leading to death of tissue and resulting in behavioral changes [1]. The prevalence of stroke is increasing in the population as the global population ages. Additionally, with the increased prevalence of risk factors, such as hypertension, the rate of ischemic strokes is increasing in younger populations [2].
The lack of oxygen and nutrients like glucose leads to impaired cellular function, leading to impairments in overall function. For example, if the blockage of blood flow is in the motor cortex, then motor function, such as walking, will likely be impaired in the patient. Within the brain, the anatomy of a stroke includes the ischemic core, where there is a significant loss of blood flow. The penumbra, the region adjacent to the core, has impaired function, but the structure is often preserved. Neurons and glial cells in the penumbra may be salvageable once reperfusion is established. Reperfusion is the return of blood flow after the thrombi have been removed, either spontaneously or surgically. Additionally, the process of reperfusion also contributes to damage in the brain [3].
There are several molecular signalling cascades that commence after the onset of stroke; these include increases in apoptosis, oxidative stress, and neuroinflammation [1]. In the brain, microglial cells are the resident immune cells present in all regions; they are related to monocyte and macrophage cells present in the peripheral immune system. Microglial cells are activated by various stimuli, including brain injury in pathological conditions. Activated microglial cells are the defense for the brain; they express various cytokines and growth factors in response to injury. They have two roles, first they act as phagocytes. Secondly, they release noxious substances, such as nitric oxide [4,5]. Neuroinflammation is a major contributing factor to damage after ischemic stroke and reperfusion, leading to the exacerbation of brain damage and related symptoms. Secondary health complications can also arise after the immune response is activated; this can include stroke-induced immunodepression syndrome (SIDS) and an increase in stroke severity [6]. The use of immunotherapies—including CAR-T cell therapy—may also be extendable to other conditions that predispose individuals to ischemic stroke, such as antiphospholipid syndrome [7].
Understanding the neuroinflammation response after ischemic stroke can lead to better therapeutic developments for affected patients. Inflammation prior to acute ischemic stroke (AIS) can play a significant role in outcomes [8,9,10]. Current established therapies for acute stroke include administering aspirin [11], which provides some benefit to patients, but the timing of administration is important [12]. Whereas corticosteroids have been shown to have no beneficial role for acute stroke [13]. The aim of this review is to provide an updated summary of how stroke impacts the immune system and how immune therapies can improve outcomes in both clinical and pre-clinical studies. We will also discuss future directions given our synthesis of the data.

2. Materials and Methods

A comprehensive literature search was conducted using PubMed to identify relevant articles published until 2024. Additional articles were identified through manual references from relevant primary articles and review papers. Only articles published in English were included. Search terms included: stroke, ischemic stroke, immune system, neuroinflammation, monocyte, immune therapy, antibodies, sex differences, sex-specific, and gene expression. Inclusion criteria were the following: studies investigating immune therapies for stroke treatment and sex differences in stroke outcomes.

3. Clinical Studies

In this section, we will review clinical studies that have characterized and investigated potential therapies targeting the immune system after ischemic stroke for patient recovery. This work has been summarized in Table 1.
Table 1. Summary of main findings of clinical studies, including study question, population, and main findings.

3.1. Targeting Inflammation

Reducing levels of neuroinflammation might decrease damaged ischemic tissue, leading to better outcomes. Combining sodium tanshinone IIA sulfonate (STS) with tissue plasminogen recombinant activator (rt-PA) reduces cerebral hemorrhagic transformation. There is an inhibition of peripheral inflammatory cells by suppressing blood-brain barrier injury, which is critical for rt-PA effectiveness [21]. To determine the extent to which leukocytes have an effect on patient recovery, one study monitored levels of circulating monocytes in stroke patients who had received rt-PA [14]. Patients with lower monocyte counts were found to be less likely to have a poor outcome after stroke, and high monocyte counts were positively correlated with increased stroke volume and worse National Institutes of Health Stroke Scale (NIHSS) scores [14]. The NIHSS is a neurological examination that assesses the effects of stroke on consciousness, motor strength, language, and other systems that may be affected in patients [25]. However, patients who had a worse outcome were also noted to have been older with a higher NIHSS score and a larger ischemic damage volume at intake, along with other attributes that may have negatively affected their outcome [14]. Building on these findings, research has delved into the specific subtypes of monocytes that may be beneficial or detrimental. A study found that targeted modulation of CD14highCD16+ monocyte cells could increase an anti-inflammatory effect in stroke patients. This study suggests that therapies enhancing this specific subset might help minimize inflammatory damage after stroke by promoting tissue repair and angiogenesis [22].
Double-negative T cells (DNTs) were also found to be involved with post-stroke neuroinflammation. In a mixed sample study, including both 80 stroke patients and 30 mice, DNT cell levels were increased in both the brain and peripheral blood of stroke patients and mice that had undergone middle cerebral artery occlusion [26]. Furthermore, coculturing of proinflammatory CD86+ microglia and anti-inflammatory CD206+ microglia with DNT cells resulted in upregulation of proinflammatory microglia and downregulation of anti-inflammatory microglia, suggesting that DNT cells play an important role in causing increased inflammation in stroke patients [26]. Similar results were also seen in mice that were deficient in recombination activating gene 1–deficient (Rag1−/−), resulting in no mature T or B cells. These deficient mice had larger infarct volumes and worse modified neurological severity, right-turn test, and latency to fall scores after receiving DNT cells from wild-type mice [26]. One of the reasons DNT cells were thought to have such an impactful role in ischemic inflammation may be due to the release of DNT-derived tumor necrosis factor alpha (TNF-alpha), which is an inflammatory cytokine linked to activation of proinflammatory microglia. Anti-FasL antibodies were used to reduce TNF-alpha levels, resulting in reduced proinflammatory microglia activation [26]. These results indicate that anti-FasL antibodies may serve as an important treatment adjunct for patients after a stroke in reducing inflammation and infarct volume, increasing chances for an improved functional outcome.
Other studies aimed at finding treatment options that reduced leukocyte levels, thereby also reducing inflammation after ischemic stroke. One of these studies evaluated the use of intravenous minocycline, a tetracycline antibiotic that has anti-inflammatory effects by inhibiting neutrophil-mediated tissue injury, on post-stroke outcomes. Patients separated into 4 groups of incremental doses, 50% had an improved modified Rankin Scale (mRS) of 0–1, which measures the degree of disability after stroke [15]. A modified Rankin Scale score of 0 or 1 was considered an excellent outcome. However, this study did not include a control group, had a small sample size, and the results were based on a single scoring process. More extensive testing may be needed before determining clinical efficacy. Additionally, one patient’s death was potentially related to minocycline [15].

3.2. Supressing the Immune System

Immunosuppression may also serve as a method of reducing inflammation after an ischemic stroke in patients by hindering lymphocyte circulation into damaged tissues. Fingolimod, an immunosuppressive drug, had decreased microvascular permeability compared to the control group [16]. By decreasing microvascular permeability, the ability of lymphocytes to leave the bloodstream and circulate into tissues may be decreased. Post-stroke patients treated with Fingolimod also had limited secondary tissue injury, with ischemic damage volume extension being significantly smaller than the control group, which was assessed using T1-weighted imaging 7 days post-stroke symptom-onset [16]. This result was most likely due to lymphocytes being less able to cross blood-tissue barriers since the microvasculature was less permeable. These patients also had attenuated neurological deficits and overall better recovery, shown by an improved mean NIHSS score of 7 from 11 after one week of treatment. Higher NIHSS scores represent worse motor and neurological deficits compared to lower NIHSS scores. Even though Fingolimod proved to have positive effects on patient recovery and improvement, the sample size of this study was very small, with 11 patients in the experimental group and 11 in the control group. Additionally, the timing of drug administration was not kept consistent in this study, but the significance of this variation was not determined. To maintain consistency and accuracy, all patients in the experimental group should have been given treatment within the same time frame after admittance. Furthermore, the ratio of female to male subjects was not equally distributed, with females only accounting for about 18% of the control group and 27% of the experimental group, making the applicability of these findings to both sexes difficult [16].
Similar results were found in a study that utilized Interluekin-37 (IL-37), an immunosuppressive cytokine thought to impact stroke outcomes [17]. In this study, circulating levels of IL-37 were 2-fold higher in ischemic stroke patients within the first 3 days post-stroke; however, there was no association of this with improved NIHSS or Glasgow Coma Scale scores [17]. The Glasgow Coma Scale is a similar method to NIHSS, measuring the level of consciousness of patients with acute brain injury based on eye, motor, and verbal functions. Human subjects in this study had very few outcome measurements; therefore implications of these findings are limited since no other assessment to correlate them with other stroke outcomes was made. This study also included work in mice, and the results will be discussed in the preclinical studies section below [17].

3.3. Antibody Therapy

The use of antibodies to target ischemic tissue and proinflammatory cytokines was a prospective treatment in reducing ischemic infarct size and improving motor outcome of post-AIS patients in the remaining studies. Natalizumab, a monoclonal antibody against alpha4 integrin, and antibody GSK249320, a humanized monoclonal antibody to myelin-associated glycoprotein, were both investigated for this purpose. Natalizumab was used in post-AIS patients to block leukocyte-endothelium adhesion and transmigration of leukocytes into ischemic tissues, therefore reducing expansion of ischemic tissue [18]. Though both groups showed lower median infarct volumes overall, there was no significant change in medians between a placebo group of 82 patients and a Natalizumab-treated group of 79 patients, which was measured using contrasted MRI from baseline to 30 days post-treatment. Other outcomes that were assessed included effects on NIHSS, mRS, and Barthel Index (BI) scores, of which only mRS and BI scores showed improvement between placebo and treatment groups, with 13 of the 72 treated patients measured on day 30 post-treatment having perfect scores. This was not considered significant compared to the placebo group, which also had 7 placebo patients having perfect scores. There was also no significant difference between NIHSS scores from baseline to 24 h or 5 days post-treatment. Therefore, based on these results, clinical function improved in both groups, but neurological deficit did not. Overall, Natalizumab did not significantly impact infarct volume or improve clinical function scores compared to a placebo group, but additional outcome measurements could have been utilized to determine the extent of Natalizumab on circulating leukocyte counts or concentration of inflammatory markers that this drug may have affected. Lastly, there were increased infections in the treatment arm, possibly due to the non-humanised form of the antibody being used. The incidence of overall infections did not appear to be increased over the background rate [18].
GSK249320 monoclonal antibody was used in a different regard, where myelin-associated glycoprotein (MAG) was targeted to determine effects on motor outcome in post-AIS patients. MAG is an inhibitory protein that prevents outgrowth of axonal myelin, which serves as a vector for neuronal communication [19]. Targeting this protein would promote neuronal repair, improving communication and motor function. This antibody was not found to have a significant impact on gait velocity, and the study was stopped after 90 days due to results meeting a predefined futility criteria cut-off. Most subjects of both groups had some level of ambulation 180 days post-treatment, but based on other endpoints, such as gait impairment category, NIHSS score, and other mobility assessment scores, there was no significant difference between the treatment and placebo group. MAG levels were drastically decreased in patients in the GSK249320-treated group between days 1 and 6 compared to patients in the placebo group. This decrease was maintained until day 30 but returned to levels like the placebo group by day 180. Based on these findings, GSK249320 antibody treatment was not deemed a promising treatment option for motor improvement in stroke patients. Follow-up studies may be needed, as the endpoints might have had too large a floor effect, and the second antibody dosage might have been too low. This study was strong in that it utilized a larger sample population from multiple centers and countries, and patient makeup was relatively consistent in both groups, increasing diversity and confidence in their findings [19].
To target pro-inflammatory cytokines instead of glycoproteins and integrins, interluekin-1 receptor antagonists (IL-1Ra) were used to combat inflammatory responses by reducing peripheral inflammatory response and decreasing interleukin-6 (IL-6) mediator levels, which are important contributors to expansion of tissue damage in post-stroke patients [20]. IL-1Ra was found to prevent plasma IL-6 concentrations from rising in the first 3 days post-treatment compared to the placebo group. C-reactive protein concentrations were also significantly reduced in the first 3 days post-treatment, but not Von Willebrand Factor (VWF) concentrations. Decreased C-reactive protein signified a reduction in inflammation; however, VWF maintained the same levels, indicating that clot formation was still present in IL-1Ra-treated patients. Serious adverse events occurred in both experimental and placebo groups. IL-1Ra treatment was not found to have a favorable mRS outcome, and more patients in the placebo group had a mRS score of 0 to 2, meaning that motor function was not significantly different between the treatment and placebo groups. However, to further evaluate clinical outcome, this study could have also utilized additional assessment scales, such as NIHSS or Barthel Index (BI) score, since mRS was the only motor function scoring system used in this study. Overall, this study indicates that IL-1Ra may be a suitable co-treatment in post-stroke patients but requires further evaluation beyond a single center with a larger sample size, thorough safety investigation, and use of more motor and neurological function scoring systems [20].

4. Preclinical Studies

Preclinical studies using model systems have been used to understand and characterize the mechanisms of the immune response after ischemic stroke. Below, we will summarize the main findings from several studies, and we have also summarized each study, including the study question, model system, stroke model, and main findings in Table 2. Throughout this section, we will mention the middle cerebral artery occlusion (MCAO) model of ischemic stroke, which is an animal stroke model in which the middle cerebral artery is occluded. After some time, the occlusion is removed to mimic reperfusion, as experienced by human stroke patients [27].
Table 2. Summary of main findings of preclinical studies.

4.1. Targeting Neuroinflammation Post-Stroke

After the onset of an ischemic stroke and subsequent reperfusion, activated leukocytes mediate neuroinflammatory responses, which is essential for removal of cellular debris. However, when the leukocytes are overactivated it can lead to the deterioration of salvageable penumbra [3,54]. One study has demonstrated that the neuroinflammatory response after an ischemic stroke can be reduced by plasmacytoid dendritic cells through microglia and regulatory T cells [28]. Using exosomes secreted from lipopolysaccharide (LPS) stimulated macrophages, neuroprotective effects were observed in vitro and in vivo stroke models. In brain tissue, ischemic damage volume was reduced, and neurological function was improved. The mechanism governing this was enhancing the microglial polarization from M1, inflammatory to M2 anti-inflammatory phenotype, thus decreasing inflammation [29]. Long-term studies are needed to identify whether these effects are maintained. Additionally, an analysis of functional outcome of animals would have provided more comprehensive data from this study.
The construction of a multifunctional nanoparticle (NP) improved MCAO-induced brain injury in male rats. The NP contained stroke-homing and blood–brain barrier targeting peptides as well as salvianic acid A, which responds to reactive oxygen species (ROS). ROS serve as signaling molecules and polarize microglia into the M1 phenotype. The M1 phenotype increases the permeability of the blood–brain barrier and allows increased leukocyte penetration as well as inflammatory cytokine secretion. Because the NP was able to eliminate ROS, regulation of microglia transformation was promoted, upholding the blood–brain barrier. The improved integrity of the blood–brain barrier led to reduced cerebral infarction, neuroinflammation, and apoptosis of neuronal cells. Improved motor and sensory function were also observed upon prolonged NP administration, though the NPs were found to distribute to a variety of metabolic organs after accumulation in the brain. Further investigation is needed to determine whether the residual NP has the potential for long-term toxicity [36].
Targeting the chemokine receptor 2 (CCR2) has provided some controversial results. Blocking the CCR2 on monocytes using a receptor antagonist, INCB 3344, worsened stroke outcome and ischemic damage volume in the brain tissue of animals after ischemic stroke, possibly because of increasing M1 polarized microglia [55]. Another study that induced stroke in CCR2 knockout mice demonstrated anti-inflammatory effects, which resulted in anti-inflammatory microglial cells and better functional outcome after stroke [56]. Manipulating the N-methyl-D-aspartate (NMDA) receptor with adeno-associated virus has also been demonstrated to have beneficial effects after ischemic stroke [33].
Chemokine-like factor 1 (CKLF1) triggers an inflammatory response of microglia which leads to the microglia entering a tolerant state and no longer responding appropriately. This decreases immune response and exacerbates ischemic stroke via the AMPK/mTOR pathway. In adult male mice, a decreased oxygen consumption rate was observed when CKLF1 was administered 1 hour before ischemia. Motor function improved when CKLF1 was inhibited by gene knockdown and antibody neutralization. Future studies may further investigate the potential for CKLF1 inhibition as a therapeutic technique [39]. The post-stroke dementia described in some patients may be mediated by B-lymphocyte infiltration [32]. As discussed above, mice deficient in T and B cells (Rag1−/−) demonstrated better stroke outcomes after day 1, including less ischemic damage volume in brain tissue and better functional scores. These measurements took place a few days after stroke. Long-term studies are needed for a better understanding of these effects [26,34]. When the current treatment for ischemic stroke, rt-PA, was combined with RTL 1000 there was no additional neuroprotective effect observed, however, the study did not include functional outcome. Transplantation of lymphocytes after ischemic stroke has been reported to decrease the number of apoptotic cells in brain tissue as well as improve functional outcome after stroke [35].
In male rats, physical exercise (PE) post-stroke can promote the expression of triggering receptors expressed on myeloid cells 2 (TREM2). Increased levels of TREM2 can be associated with long-term recovery of neurological function due to its promoting the expression of activin-A, an important component in PE-induced oligodendrogenesis [38].
Though the involvement of interleukins (IL) has been described in the clinical population, to better understand their role in ischemic stroke, model systems have been investigated. Mice transgenic for human IL-37 had an 8-fold higher level of plasma IL-37 24 h post-stroke compared to control animals, which were induced under anesthesia with exposure of the right carotid bifurcation but did not receive the filament used for MCAO in the stroke surgical mice [17]. This meant that both groups of mice were transgenic for human IL-37, but only the group that had undergone stroke had elevated plasma IL-37 concentrations. Increased expression of IL-37 mRNA had a strong negative correlation with clinical score post-stroke in transgenic mice, but actual plasma IL-37 protein did not. This was thought to be consistent with locally produced IL-37 mRNA in the brain having greater neuroprotective capabilities than circulating IL-37 protein. There were also no significant effects of IL-37 on regional cerebral blood flow or motor function, but they did find that transgenic mice travelled 2.5 times further and had a 2-fold higher maximum speed than wild-type mice [17]. Even though the difference in motor function was not significant, there was still evidence of mice having less severe locomotor deficits if able to produce IL-37. The role of IL-1 is a bit more complicated, in that there are two forms, A and B. When both are knocked out, there is a protective effect on ischemic damage volume compared to controls or single knockout animals [44]. This study only included male animals, so it would be beneficial to examine the role and impact of IL-1 in females with ischemic stroke. To reduce inflammation after a stroke, IL-4 has been administered as it has anti-inflammatory properties. Data from 1 and 7 days showed increased levels of anti-inflammatory markers, but neurodegeneration and myelin damage were still present. More long-term studies, as well as functional outcomes in animals, should be measured [46].
Cornuside, a molecule which inhibits the IL-17F/TRAF6/NF- κB pathway, offers another potential treatment for stroke-affected patients. In 8-week-old male Sprague-Dawley rats, post-stroke cornuside administration was linked to a decrease in the expression of IL-1, which maintained the integrity of the blood-brain barrier. This led to a reduction in both intestinal and neuroinflammation [51].
Intranasal administration of IL-13 was found to decrease neuron loss, exert a neuroprotective effect, and promote the integrity of white matter after ischemic stroke in adult male mice. The treatment was also able to reduce inflammation without altering the leukocyte population in the brain. The study suggests the Janus Kinase-Signal Transducer Activator (JAK-STAT) signaling pathway may be involved in the regulatory activities of IL-13, though additional research would be necessary to further investigate this [45].

4.2. Targeting Innate Immune System Post-Stroke

The innate immune system plays a role after ischemic stroke via TLRs. There is an increase in the expression of TLR-4 in the brain and microvasculature of animals post-stroke. Inhibiting TLR-4 after reperfusion prevents ischemic injury and improves functional outcome [48]. Two different strains of male mice were used in this study; expanding the study to include females would be beneficial. Another study showed similar findings when inhibiting TLR-4 using a monoclonal antibody, which provided decreased ischemic damage volume and reduced neurological deficits after ischemic stroke only when it was administered intra-arterially or venously [47].
Early infiltration after ischemic stroke by T-regulatory-like (TRLs) cells Cd8+CD122+CD49dlo (CD8+ TRLs), reduces inflammation and demonstrates neuroprotective activity in mice of both sexes. The CD8+ TRLs were found to infiltrate via the CXCL10/CXCR3 chemokine/receptor axis and alleviate post-stroke inflammation via production of IL-10. Epidermal growth factor-like transforming growth factor (ETGF) is present in CD8+ TRLs and is believed to be responsible for the neuroprotective characteristics of the cells. Intravenous treatment of CD8+ TRLs showed a reduction in infarction and promoted the long-term recovery in both male and female mice, posing potential for clinical implementation [40].
Cottonseed oil (CSO) has demonstrated some neuroprotective effects in adult male rats via the toll-like receptor 4/nuclear factor kappa B (TLR4/NF- κB) pathway. The treatment group demonstrated a significant decrease in brain water volume as well as increased inhibition of microglia and astrocyte inflammation [37].

4.3. Antibody Therapies to Promote Improved Outcomes Post-Stroke

Minocycline is an antibiotic used to treat bacterial infection and has been described to impact stroke outcome. In neonatal brain injury, minocycline has been reported to decrease ischemic damage as well as reduce neurodegeneration [49]. In male rats, minocycline administered pre-stroke reduced ischemic damage, possibly through reduced proinflammatory signalling. It is important to note that there was no behavioral analysis in terms of functional outcome measured in these rats; only brain tissue was analyzed [50]. Targeting leukocytes by using antibodies against the leukocyte adhesion molecules demonstrated no protective effect after ischemic stroke [42]. Antibodies targeting myelin-associated glycoprotein after ischemic stroke reduced ischemic damage volumes in brain tissue 7 days post-operatively, though the most beneficial effect was observed 24 h after ischemic stroke [41].
Programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2) behave pathogenically in ischemic stroke, and one study investigates the use of anti-PD-L monoclonal antibody (mAb) as therapy for MCAO. Ninety-six hours post-mAb injection, male mice performed better on behavioral assessment, had smaller areas of neurodegeneration, less spleen damage, fewer glial cells in the brain, and increased CD8+ TRLs. This presents a possibility for mAb treatment to be implicated in clinical stroke patients [43].

5. Sex Differences

A substantial body of research has provided clear evidence of the existence of sex differences in ischemic stroke risk and outcome [23,52,53,57]. It has been found that women are at a disproportionately higher risk of stroke mortality and disability than men, while men exhibit higher numbers in stroke onset [53,57]. However, we see an inverse trend in studies done in neonatal, pre-adolescent and adolescent children, with a higher prevalence of stroke and worse stroke outcomes being observed in boys [24]. This age-dependent reversal suggests complex interactions between hormonal, genetic, and developmental factors.
Clinically, a study on patients with cardioembolic stroke showed sexual dimorphism in the early immune response, gene expression in cell death, and for genes specifically expressed by neutrophils following cardioembolic stroke. Early immune responses at the ≤ 3 h timepoint in females expressed an overrepresentation of multiple interconnected pathways including TLR (Toll-like receptor), HMGB1, TREM1, PPARa/RXRa, hypoxia, renin-angiotensin, mitochondrial dysfunction, glucocorticoid receptor and cytokine signaling pathway. These pathways play a role in preconditioning, central nervous system and periphery connection after stroke, ROS generation and cytokine production. While males had a higher expression of convergent nodes on CREB, caspase-1, and ERK1/2. The ischemia triggered phosphorylation of CREB, and subsequent CRE-mediated gene expression led to the expression of neuroprotective molecules while CASP1 played a role in the initiation of inflammation via IL-1β activation. In the cell death pathways, at the ≤ 3 h timepoint 217 molecules participated in cell death in the females while there were only 22 molecules in the males, and 18 out of the 22 molecules in males were common in both sexes. Inflammatory responses were also female specific at this timepoint. Regarding cell-specific transcriptional changes in immune cells, females predominantly exhibited neutrophil-specific genes at the ≤3 h, 5 h and 24 h timepoints, while males only showed changes at 5 h that then increased at 24 h. These variations in gene expression contribute to the sex differences seen in stroke outcomes [23].
Beyond differences in gene expression patterns, the protective mechanism of estrogen is thought to be responsible in regulating microglial activation in females. Researchers described an increase in microglia activity in brain tissue three days after the induction of ischemic stroke using the MCAO model. There were increased levels of TNFα and ptgs2 (Cox-2) expression in male mice compared to females [52]. A higher immune response was also observed in aged male mice following MCAO, they had higher levels of CD8+ T and regulatory T cells in the brain when compared to the females [53]. T lymphocytes are increasingly being recognized as key modulators in the detrimental inflammatory and thrombogenic responses associated with ischemic stroke [55,58]. The elevated immune response seen in males suggests that they may be more susceptible to increased tissue damage and infarct size than females following stroke induction.

6. Conclusions

The evidence from the clinical and preclinical studies presented in this review, it is evident that modulating neuroinflammation after stroke is important. Currently, tissue-type plasminogen activator (tPA), also known as alteplase, is the only FDA approved therapeutic for patients suffering from an ischemic stroke and the therapeutic window is limited. A mechanical thrombectomy has been shown to be beneficial for patients with proximal, large vessel occlusions up to 24 hours after stroke onset [56]. Other therapeutic options for ischemic stroke patients are needed. Recent data has revealed the Tenecteplase, is another thrombolytic agent but is manufactured by recombinant DNA technology. It has been shown to lyse large vessel clots more effectively and can be administered in a single-dose intravenously [56,59]. Additionally, targeting thrombo-inflammation using the ADAMTS13/von Willebrand axis to predict outcomes in ischemic stroke patients [60].
In terms of the data and the future for ischemic stroke therapeutics, a combination of treatments is likely to be more effective based on the data [61,62]. This could include reducing neuroinflammation through immune therapy and lifestyle changes (e.g., diet), which could provide more opportunities for recovery in stroke affected patients. Our work in mouse models has shown that motor training every day after stroke promotes recovery of function [63] and in other work we have shown that increases in B-vitamins and choline post-stroke helps with increasing better stroke outcomes [64,65] when the sensorimotor cortex is damaged.
Furthermore, sex differences are highly prevalent after ischemic stroke. The utilization of both male and female animals in preclinical work and patients in clinical work is critical in the forward progression of healthcare. These differences can inform us of the best sex-specific interventions, treatments or techniques that could be used in healthcare to ensure lower mortality rates and higher quality of life for both men and women.
Stroke has a higher prevalence in aging populations [66]. It should be noted that in recent years a worldwide trend for increased incidence of ischemic strokes in younger patients has been observed [2]. In terms of aging, the immune system also undergoes significant changes as people age [67]. Understanding these changes and how they then impact stroke outcomes will provide important insights. The lack of preclinical work conducted in aged animals needs to be increased, both female and male mice need to be included [68]. Stroke is a result of several diseases coming together and understanding those complex interactions will provide more insight into effective therapeutic development.

Author Contributions

Conceptualization, N.M.J.; methodology, N.M.J., L.H., K.P., and R.M.M.; investigation, N.M.J., L.H., K.P., and R.M.M.; data curation, N.M.J., L.H., K.P., and R.M.M.; writing—original draft preparation, N.M.J., L.H., K.P., and R.M.M.; writing—review and editing, N.M.J., L.H., K.P., and R.M.M.; visualization, N.M.J.; supervision, N.M.J.; project administration, N.M.J. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Data Availability Statement

No new data were created or analyzed in this study.

Acknowledgments

The authors want to acknowledge Hassanat Etti-Balogun for her contributions to the graphical abstract and comments on the text.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
AISAcute ischemic stroke
ACSAnterior circulation stroke
BBBBlood–Brain Barrier
BIBarthel Index
BMVECsbrain microvascular endothelial cells
CKLF1chemokine like factor 1
CCR2chemokine receptor 2
CNSCentral Nervous System
CRPC-reactive protein
CSOcottonseed oil
dMCAOdistal middle cerebral artery occlusion
ET-1Endothelin-1
ETGFepidermal growth factor–like transforming growth factor
DNTDouble-negative T cells
FasLFas ligand
FBGFasting blood glucose
FITCfluorescein isothiocyanate
Γδgamma delta T cells
GFAPglial fibrillary acidic protein
GKGoto-Kakizaki
HBMECshuman brain microvascular endothelial cells
H-Ihypoxic-ischemic
ICAM-1intracellular adhesion molecule 1
ICEinterleukin-1β converting enzyme
IFN-γInterferon gamma
IgAimmunoglobulin A
IgGimmunoglobulin G
ILInterleukin
KOknockout
LPS-Exlipopolysaccharide exosomes
LTPlong-term potentiation
LTlymphocyte transplant
mAbmonoclonal antibody
MCAOMiddle Cerebral artery occulsion
MCAO/Rmiddle cerebral artery occlusion/reperfusion
MoDMsmonocyte-derived macrophages
mRSmodified Rankin Scale
MAGmyelin-associated glycoprotein
MD2myeloid differentiation factor 2
muMtHomozygous mutant mice that lack mature B cells
NMDAN-methyl-D-aspartate
NMDAR N-methyl-D-aspartate receptors
NHSSNational Institutes of Health Stroke Scale
NKTnatural killer T cells
PARPpoly(ADP-ribose) polymerase
PBSphosphate buffered saline
PEphysical exercise
pDCsplasmacytoid dendritic cells
PD-L1programmed death ligand 1
PGE2prostaglandin E2
pMCAOpermanent proximal middle cerebral artery occlusion
PCSposterior circulation stroke
ROSreactive oxygen species (ROS)
STSsodium tanshinone IIA sulfonate
SIDSstroke-induced immunodepression syndrome
TCRT cell receptor
Tregsregulatory T cells
TLRtoll-like receptor
tMCAOtransient middle cerebral artery occlusion
TNF-αtumor necrosis factor alpha
tPAtissue-type plasminogen activator
TRLsT regulatory-like cells
TREM2triggering receptor expressed on myeloid cells 2
SISStroke impact scale
VEGF-Avascular endothelial growth factor A
VWFVon Willebrand factor
WTwild type

References

  1. Mendelow, A.D. Stroke: Pathophysiology, Diagnosis, and Management; Elsevier: Amsterdam, The Netherlands, 2015. [Google Scholar]
  2. Cabral, N.L.; Freire, A.T.; Conforto, A.B.; dos Santos, N.; Reis, F.I.; Nagel, V.; Guesser, V.V.; Safanelli, J.; Longo, A.L. Increase of Stroke Incidence in Young Adults in a Middle-Income Country. Stroke 2017, 48, 2925–2930. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  3. Pan, J.; Konstas, A.-A.; Bateman, B.; Ortolano, G.A.; Pile-Spellman, J. Reperfusion Injury Following Cerebral Ischemia: Pathophysiology, MR Imaging, and Potential Therapies. Neuroradiology 2007, 49, 93–102. [Google Scholar] [CrossRef] [Scilit]
  4. Dheen, S.T.; Kaur, C.; Ling, E.-A. Microglial Activation and Its Implications in the Brain Diseases. Curr. Med. Chem. 2007, 14, 1189–1197. [Google Scholar] [CrossRef] [Scilit]
  5. Gehrmann, J.; Matsumoto, Y.; Kreutzberg, G.W. Microglia: Intrinsic Immuneffector Cell of the Brain. Brain Res. Rev. 1995, 20, 269–287. [Google Scholar] [CrossRef] [Scilit]
  6. Jiang, C.; Kong, W.; Wang, Y.; Ziai, W.; Yang, Q.; Zuo, F.; Li, F.; Wang, Y.; Xu, H.; Li, Q.; et al. Changes in the Cellular Immune System and Circulating Inflammatory Markers of Stroke Patients. Oncotarget 2017, 8, 3553–3567. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  7. Evangelidis, P.; Kotsiou, N.; Kalmoukos, P.; Ntova, Z.; Papadopoulou, T.; Chissan, S.; Sarvani, A.; Kokoris, S.; Grouzi, E.; Doumas, M.; et al. Prevalence and Risk Factors of Acute Ischemic Stroke in Patients with Antiphospholipid Syndrome: A Retrospective Monocenter Analysis. J. Cardiovasc. Dev. Dis. 2025, 12, 183. [Google Scholar] [CrossRef] [Scilit]
  8. Zhou, Y.; Zhang, Y.; Cui, M.; Zhang, Y.; Shang, X. Prognostic Value of the Systemic Inflammation Response Index in Patients with Acute Ischemic Stroke. Brain Behav. 2022, 12, e2619. [Google Scholar] [CrossRef] [Scilit]
  9. Huang, H.; Wang, W.; Ma, Q.; Cao, K. Systemic Inflammation–Based Hematological Indices and 90-Day Functional Outcomes after Intravenous Thrombolysis in Acute Ischemic Stroke: A Systematic Review. Front. Neurol. 2025, 16, 1699939. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  10. Fakhari, M.S.; Poorsaadat, L.; Almasi-Hashiani, A.; Ebrahimi-Monfared, M. Inflammatory Markers and Functional Outcome Score in Different Subgroups of Ischaemic Stroke: A Prospective Cohort Study. BMJ Neurol. Open 2024, 6, e000556. [Google Scholar] [CrossRef] [Scilit]
  11. Chen, Z.; Sandercock, P.; Pan, H.; Counsell, C.; Collins, R.; Liu, L.; Xie, J.; Warlow, C.; Peto, R. Indications for Early Aspirin Use in Acute Ischemic Stroke. Stroke 2000, 31, 1240–1249. [Google Scholar] [CrossRef] [Scilit]
  12. Murphy, A.; Hamilton, L.A.; Farley, K.; Rowe, S.A.; Christianson, T.; Medenwald, B. Low Dose Aspirin Initiation 18 Hours After Thrombolytic Therapy in Acute Ischemic Stroke. Neurologist 2024, 29, 294–298. [Google Scholar] [CrossRef] [Scilit]
  13. Poungvarin, N. Steroids Have No Role in Stroke Therapy. Stroke 2004, 35, 229–230. [Google Scholar] [CrossRef] [Scilit]
  14. Dong, X.; Nao, J.; Gao, Y. Peripheral Monocyte Count Predicts Outcomes in Patients with Acute Ischemic Stroke Treated with rtPA Thrombolysis. Neurotox. Res. 2020, 37, 469–477. [Google Scholar] [CrossRef] [Scilit]
  15. Fagan, S.C.; Waller, J.L.; Nichols, F.T.; Edwards, D.J.; Pettigrew, L.C.; Clark, W.M.; Hall, C.E.; Switzer, J.A.; Ergul, A.; Hess, D.C. Minocycline to Improve Neurologic Outcome in Stroke (MINOS): A Dose-Finding Study. Stroke 2010, 41, 2283–2287. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  16. Fu, Y.; Zhang, N.; Ren, L.; Yan, Y.; Sun, N.; Li, Y.-J.; Han, W.; Xue, R.; Liu, Q.; Hao, J.; et al. Impact of an Immune Modulator Fingolimod on Acute Ischemic Stroke. Proc. Natl. Acad. Sci. USA 2014, 111, 18315–18320. [Google Scholar] [CrossRef] [Scilit]
  17. Zhang, S.R.; Nold, M.F.; Tang, S.-C.; Bui, C.B.; Nold, C.A.; Arumugam, T.V.; Drummond, G.R.; Sobey, C.G.; Kim, H.A. IL-37 Increases in Patients after Ischemic Stroke and Protects from Inflammatory Brain Injury, Motor Impairment and Lung Infection in Mice. Sci. Rep. 2019, 9, 6922. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  18. Elkins, J.; Veltkamp, R.; Montaner, J.; Johnston, S.C.; Singhal, A.B.; Becker, K.; Lansberg, M.G.; Tang, W.; Chang, I.; Muralidharan, K.; et al. Safety and Efficacy of Natalizumab in Patients with Acute Ischaemic Stroke (ACTION): A Randomised, Placebo-Controlled, Double-Blind Phase 2 Trial. Lancet Neurol. 2017, 16, 217–226. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  19. Cramer, S.C.; Enney, L.A.; Russell, C.K.; Simeoni, M.; Thompson, T.R. Proof-of-Concept Randomized Trial of the Monoclonal Antibody GSK249320 Versus Placebo in Stroke Patients. Stroke 2017, 48, 692–698. [Google Scholar] [CrossRef] [Scilit]
  20. Smith, C.J.; Hulme, S.; Vail, A.; Heal, C.; Parry-Jones, A.R.; Scarth, S.; Hopkins, K.; Hoadley, M.; Allan, S.M.; Rothwell, N.J.; et al. SCIL-STROKE (Subcutaneous Interleukin-1 Receptor Antagonist in Ischemic Stroke): A Randomized Controlled Phase 2 Trial. Stroke 2018, 49, 1210–1216. [Google Scholar] [CrossRef] [Scilit]
  21. Ji, B.; Zhou, F.; Han, L.; Yang, J.; Fan, H.; Li, S.; Li, J.; Zhang, X.; Wang, X.; Chen, X.; et al. Sodium Tanshinone IIA Sulfonate Enhances Effectiveness Rt-PA Treatment in Acute Ischemic Stroke Patients Associated with Ameliorating Blood-Brain Barrier Damage. Transl. Stroke Res. 2017, 8, 334–340. [Google Scholar] [CrossRef] [Scilit]
  22. Urra, X.; Villamor, N.; Amaro, S.; Gómez-Choco, M.; Obach, V.; Oleaga, L.; Planas, A.M.; Chamorro, A. Monocyte Subtypes Predict Clinical Course and Prognosis in Human Stroke. J. Cereb. Blood Flow Metab. 2009, 29, 994–1002. [Google Scholar] [CrossRef] [Scilit]
  23. Stamova, B.; Jickling, G.C.; Ander, B.P.; Zhan, X.; Liu, D.; Turner, R.; Ho, C.; Khoury, J.C.; Bushnell, C.; Pancioli, A.; et al. Gene Expression in Peripheral Immune Cells Following Cardioembolic Stroke Is Sexually Dimorphic. PLoS ONE 2014, 9, e102550. [Google Scholar] [CrossRef] [Scilit]
  24. Golomb, M.R.; Fullerton, H.J.; Nowak-Gottl, U.; deVeber, G. Male Predominance in Childhood Ischemic Stroke. Stroke 2009, 40, 52–57. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  25. Lyden, P. Using the National Institutes of Health Stroke Scale. Stroke 2017, 48, 513–519. [Google Scholar] [CrossRef] [Scilit]
  26. Meng, H.; Zhao, H.; Cao, X.; Hao, J.; Zhang, H.; Liu, Y.; Zhu, M.; Fan, L.; Weng, L.; Qian, L.; et al. Double-Negative T Cells Remarkably Promote Neuroinflammation after Ischemic Stroke. Proc. Natl. Acad. Sci. USA 2019, 116, 5558–5563. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  27. Kleinschnitz, C.; Fluri, F.; Schuhmann, M. Animal Models of Ischemic Stroke and Their Application in Clinical Research. Drug Des. Dev. Ther. 2015, 9, 3445–3454. [Google Scholar] [CrossRef] [Scilit]
  28. Chen, C.; Chencheng, Z.; Cuiying, L.; Xiaokun, G. Plasmacytoid Dendritic Cells Protect Against Middle Cerebral Artery Occlusion Induced Brain Injury by Priming Regulatory T Cells. Front. Cell. Neurosci. 2020, 14, 8. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  29. Zheng, Y.; He, R.; Wang, P.; Shi, Y.; Zhao, L.; Liang, J. Exosomes from LPS-Stimulated Macrophages Induce Neuroprotection and Functional Improvement after Ischemic Stroke by Modulating Microglial Polarization. Biomater. Sci. 2019, 7, 2037–2049. [Google Scholar] [CrossRef] [Scilit]
  30. Chu, H.X.; Broughton, B.R.S.; Kim, H.A.; Lee, S.; Drummond, G.R.; Sobey, C.G. Evidence That Ly6C(Hi) Monocytes Are Protective in Acute Ischemic Stroke by Promoting M2 Macrophage Polarization. Stroke 2015, 46, 1929–1937. [Google Scholar] [CrossRef] [Scilit]
  31. Fang, W.; Zhai, X.; Han, D.; Xiong, X.; Wang, T.; Zeng, X.; He, S.; Liu, R.; Miyata, M.; Xu, B.; et al. CCR2-Dependent Monocytes/Macrophages Exacerbate Acute Brain Injury but Promote Functional Recovery after Ischemic Stroke in Mice. Theranostics 2018, 8, 3530–3543. [Google Scholar] [CrossRef] [Scilit]
  32. Doyle, K.P.; Quach, L.N.; Solé, M.; Axtell, R.C.; Nguyen, T.-V.V.; Soler-Llavina, G.J.; Jurado, S.; Han, J.; Steinman, L.; Longo, F.M.; et al. B-Lymphocyte-Mediated Delayed Cognitive Impairment Following Stroke. J. Neurosci. 2015, 35, 2133–2145. [Google Scholar] [CrossRef] [Scilit]
  33. During, M.J.; Symes, C.W.; Lawlor, P.A.; Lin, J.; Dunning, J.; Fitzsimons, H.L.; Poulsen, D.; Leone, P.; Xu, R.; Dicker, B.L.; et al. An Oral Vaccine Against NMDAR1 with Efficacy in Experimental Stroke and Epilepsy. Science 2000, 287, 1453–1460. [Google Scholar] [CrossRef] [Scilit]
  34. Kleinschnitz, C.; Schwab, N.; Kraft, P.; Hagedorn, I.; Dreykluft, A.; Schwarz, T.; Austinat, M.; Nieswandt, B.; Wiendl, H.; Stoll, G. Early Detrimental T-Cell Effects in Experimental Cerebral Ischemia Are Neither Related to Adaptive Immunity nor Thrombus Formation. Blood 2010, 115, 3835–3842. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  35. Zhao, Y.; Zhu, T.; Li, H.; Zhao, J.; Li, X. Transplantation of Lymphocytes Co-Cultured with Human Cord Blood-Derived Multipotent Stem Cells Attenuates Inflammasome Activity in Ischemic Stroke. Clin. Interv. Aging 2019, 14, 2261–2271. [Google Scholar] [CrossRef] [Scilit]
  36. Li, Y.; Liao, J.; Xiong, L.; Xiao, Z.; Ye, F.; Wang, Y.; Chen, T.; Huang, L.; Chen, M.; Chen, Z.-S.; et al. Stepwise Targeted Strategies for Improving Neurological Function by Inhibiting Oxidative Stress Levels and Inflammation Following Ischemic Stroke. J. Control. Release 2024, 368, 607–622. [Google Scholar] [CrossRef] [Scilit]
  37. Liu, M.; Xu, Z.; Wang, L.; Zhang, L.; Liu, Y.; Cao, J.; Fu, Q.; Liu, Y.; Li, H.; Lou, J.; et al. Cottonseed Oil Alleviates Ischemic Stroke Injury by Inhibiting the Inflammatory Activation of Microglia and Astrocyte. J. Neuroinflamm. 2020, 17, 270. [Google Scholar] [CrossRef] [Scilit]
  38. Xu, J.; Zhang, L.; Li, M.; He, X.; Luo, J.; Wu, R.; Hong, Z.; Zheng, H.; Hu, X. TREM2 Mediates Physical Exercise-Promoted Neural Functional Recovery in Rats with Ischemic Stroke via Microglia-Promoted White Matter Repair. J. Neuroinflamm. 2023, 20, 50. [Google Scholar] [CrossRef] [Scilit]
  39. Ma, W.; Wu, Q.; Wang, S.; Wang, H.; Ye, J.; Sun, H.; Feng, Z.; He, W.; Chu, S.; Zhang, Z.; et al. A Breakdown of Metabolic Reprogramming in Microglia Induced by CKLF1 Exacerbates Immune Tolerance in Ischemic Stroke. J. Neuroinflamm. 2023, 20, 97. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  40. Cai, W.; Shi, L.; Zhao, J.; Xu, F.; Dufort, C.; Ye, Q.; Yang, T.; Dai, X.; Lyu, J.; Jin, C.; et al. Neuroprotection against Ischemic Stroke Requires a Specific Class of Early Responder T Cells in Mice. J. Clin. Investig. 2022, 132, e157678. [Google Scholar] [CrossRef] [Scilit]
  41. Cash, D.; Easton, A.C.; Mesquita, M.; Beech, J.; Williams, S.; Lloyd, A.; Irving, E.; Cramer, S.C. GSK249320, A Monoclonal Antibody Against the Axon Outgrowth Inhibition Molecule Myelin-Associated Glycoprotein, Improves Outcome of Rodents with Experimental Stroke. J. Neurol. Exp. Neurosci. 2016, 2, 28–33. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  42. Bowes, M.P.; Zivin, J.A.; Rothlein, R. Monoclonal Antibody to the ICAM-1 Adhesion Site Reduces Neurological Damage in a Rabbit Cerebral Embolism Stroke Model. Exp. Neurol. 1993, 119, 215–219. [Google Scholar] [CrossRef] [Scilit]
  43. Bodhankar, S.; Chen, Y.; Lapato, A.; Dotson, A.L.; Wang, J.; Vandenbark, A.A.; Saugstad, J.A.; Offner, H. PD-L1 mAb Treats Ischemic Stroke by Controlling CNS Inflammation. Stroke 2015, 46, 2926–2934. [Google Scholar] [CrossRef] [Scilit]
  44. Boutin, H.; LeFeuvre, R.A.; Horai, R.; Asano, M.; Iwakura, Y.; Rothwell, N.J. Role of IL-1α and IL-1β in Ischemic Brain Damage. J. Neurosci. 2001, 21, 5528–5534. [Google Scholar] [CrossRef] [Scilit]
  45. Chen, D.; Li, J.; Huang, Y.; Wei, P.; Miao, W.; Yang, Y.; Gao, Y. Interleukin 13 Promotes Long-Term Recovery After Ischemic Stroke by Inhibiting the Activation of STAT3. J. Neuroinflamm. 2022, 19, 112. [Google Scholar] [CrossRef] [Scilit]
  46. Lively, S.; Hutchings, S.; Schlichter, L.C. Molecular and Cellular Responses to Interleukin-4 Treatment in a Rat Model of Transient Ischemia. J. Neuropathol. Exp. Neurol. 2016, 75, 1058–1071. [Google Scholar] [CrossRef] [Scilit]
  47. Andresen, L.; Theodorou, K.; Grünewald, S.; Czech-Zechmeister, B.; Könnecke, B.; Lühder, F.; Trendelenburg, G. Evaluation of the Therapeutic Potential of Anti-TLR4-Antibody MTS510 in Experimental Stroke and Significance of Different Routes of Application. PLoS ONE 2016, 11, e0148428. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  48. Abdul, Y.; Abdelsaid, M.; Li, W.; Webb, R.C.; Sullivan, J.C.; Dong, G.; Ergul, A. Inhibition of Toll like Receptor-4 (TLR-4) Improves Neurobehavioral Outcomes After Acute Ischemic Stroke in Diabetic Rats: Possible Role of Vascular Endothelial TLR-4. Mol. Neurobiol. 2019, 56, 1607–1617. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  49. Arvin, K.L.; Han, B.H.; Du, Y.; Lin, S.-Z.; Paul, S.M.; Holtzman, D.M. Minocycline Markedly Protects the Neonatal Brain Against Hypoxic-Ischemic Injury. Ann. Neurol. 2002, 52, 54–61. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  50. Yrjanheikki, J.; Tikka, T.; Keinanen, R.; Goldsteins, G.; Chan, P.H.; Koistinaho, J. A Tetracycline Derivative, Minocycline, Reduces Inflammation and Protects against Focal Cerebral Ischemia with a Wide Therapeutic Window. Proc. Natl. Acad. Sci. USA 1999, 96, 13496–13500. [Google Scholar] [CrossRef] [Scilit]
  51. Yan, C.; Liu, Z.; Xie, W.; Zhang, T.; Zhang, J.; Li, G.; Xu, X.; Ye, L.; Gong, J. Cornuside Protects against Ischemic Stroke in Rats by Suppressing the IL-17F/TRAF6/NF-κB Pathway via the Brain-Gut Axis. Exp. Neurol. 2024, 373, 114672. [Google Scholar] [CrossRef] [Scilit]
  52. Villapol, S.; Faivre, V.; Joshi, P.; Moretti, R.; Besson, V.C.; Charriaut-Marlangue, C. Early Sex Differences in the Immune-Inflammatory Responses to Neonatal Ischemic Stroke. Int. J. Mol. Sci. 2019, 20, 3809. [Google Scholar] [CrossRef] [Scilit]
  53. Ahnstedt, H.; Patrizz, A.; Chauhan, A.; Roy-O’Reilly, M.; Furr, J.W.; Spychala, M.S.; D’Aigle, J.; Blixt, F.W.; Zhu, L.; Bravo Alegria, J.; et al. Sex Differences in T Cell Immune Responses, Gut Permeability and Outcome After Ischemic Stroke in Aged Mice. Brain Behav. Immun. 2020, 87, 556–567. [Google Scholar] [CrossRef] [Scilit]
  54. Alsbrook, D.L.; Di Napoli, M.; Bhatia, K.; Biller, J.; Andalib, S.; Hinduja, A.; Rodrigues, R.; Rodriguez, M.; Sabbagh, S.Y.; Selim, M.; et al. Neuroinflammation in Acute Ischemic and Hemorrhagic Stroke. Curr. Neurol. Neurosci. Rep. 2023, 23, 407–431. [Google Scholar] [CrossRef] [Scilit]
  55. Liesz, A.; Zhou, W.; Mracskó, É.; Karcher, S.; Bauer, H.; Schwarting, S.; Sun, L.; Bruder, D.; Stegemann, S.; Cerwenka, A.; et al. Inhibition of Lymphocyte Trafficking Shields the Brain Against Deleterious Neuroinflammation after Stroke. Brain 2011, 134, 704–720. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  56. Xiong, Y.; Wakhloo, A.K.; Fisher, M. Advances in Acute Ischemic Stroke Therapy. Circ. Res. 2022, 130, 1230–1251. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  57. Rexrode, K.M.; Madsen, T.E.; Yu, A.Y.X.; Carcel, C.; Lichtman, J.H.; Miller, E.C. The Impact of Sex and Gender on Stroke. Circ. Res. 2022, 130, 512–528. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  58. Yilmaz, G.; Arumugam, T.V.; Stokes, K.Y.; Granger, D.N. Role of T Lymphocytes and Interferon-γ in Ischemic Stroke. Circulation 2006, 113, 2105–2112. [Google Scholar] [CrossRef] [Scilit]
  59. Bach, K.-T.; Lui, F. Tenecteplase. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2025. [Google Scholar]
  60. Makris, M.; Gavriilaki, E.; Ztriva, E.; Evangelidis, P.; Lefkou, E.; Vlachaki, E.; Bountola, S.; Perifanis, V.; Matsagkas, M.; Savopoulos, C.; et al. Prospective Study of ADAMTS13 and von Willebrand Factor’s Role in the Prediction of Outcomes in Acute Ischemic Stroke. J. Clin. Med. 2025, 14, 2470. [Google Scholar] [CrossRef] [Scilit]
  61. Wang, Y.; Li, Q.; Wang, J.; Zhuang, Q.-K.; Zhang, Y.-Y. Combination of Thrombolytic Therapy and Neuroprotective Therapy in Acute Ischemic Stroke: Is It Important? Eur. Rev. Med. Pharmacol. Sci. 2015, 19, 416–422. [Google Scholar]
  62. Knecht, T.; Borlongan, C.; dela Peña, I. Combination Therapy for Ischemic Stroke: Novel Approaches to Lengthen Therapeutic Window of Tissue Plasminogen Activator. Brain Circ. 2018, 4, 99–108. [Google Scholar] [CrossRef] [Scilit]
  63. Jadavji, N.; Emmerson, J.T.; Shanmugalingam, U.; Willmore, W.G.; Macfarlane, A.J.; Smith, P.D. A Genetic Deficiency in Folic Acid Metabolism Impairs Recovery after Ischemic Stroke. Exp. Neurol. 2018, 309, 14–22. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  64. Jadavji, N.M.; Emmerson, J.; Willmore, W.G.; MacFarlane, A.J.; Smith, P. B-Vitamin and Choline Supplementation Increases Neuroplasticity and Recovery after Stroke. Neurobiol. Dis. 2017, 103, 89–100. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  65. Jadavji, N.M.; Mosnier, H.; Kelly, E.; Lawrence, K.; Cruickshank, S.; Stacey, S.; McCall, A.; Dhatt, S.; Arning, E.; Bottiglieri, T.; et al. One-Carbon Metabolism Supplementation Improves Outcome after Stroke in Aged Male MTHFR-Deficient Mice. Neurobiol. Dis. 2019, 132, 104613. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  66. Palaniappan, L.P.; Allen, N.B.; Almarzooq, Z.I.; Anderson, C.A.M.; Arora, P.; Avery, C.L.; Baker-Smith, C.M.; Bansal, N.; Currie, M.E.; Earlie, R.S.; et al. 2026 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. Circulation 2026. [Google Scholar] [CrossRef] [Scilit]
  67. Weyand, C.M.; Goronzy, J.J. Aging of the Immune System. Mechanisms and Therapeutic Targets. Ann. Am. Thorac. Soc. 2016, 13, S422–S428. [Google Scholar] [CrossRef] [Scilit]
  68. Ayata, C.; Bath, P.M.; Planas, A.M.; Allan, S.M.; Boltze, J.; Cabeen, R.P.; Gibson, C.L.; Cipolla, M.J.; Diniz, M.A.; Fumagalli, S.; et al. Preclinical Ischemic Stroke Multicenter Trials (PRISM) Collective Statement: Opportunities, Challenges, and Recommendations for a New Era. Stroke 2026, 57, e12–e40. [Google Scholar] [CrossRef] [Scilit]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.